Genoscience is proud to announce the out-licensing of GNS561 in the cholangiocarcinoma in the United States / Canada and Europe territories to GENFIT. It is a new starting point for the company and GNS561.
GENFIT will start a Phase 2 program in 2022 in cholangiocarcinoma.
Genoscience Pharma will pursue its development in other oncology indications.
#oncology #development #autophagy
211217 – Genoscience deal PR ENG